Saltar al contenido
Merck

Structural variation cooperates with permissive chromatin to control enhancer hijacking-mediated oncogenic transcription.

Blood (2023-03-23)
Giovanni A Botten, Yuannyu Zhang, Kseniia Dudnyk, Yoon Jung Kim, Xin Liu, Jacob T Sanders, Aygun Imanci, Nathalie Droin, Hui Cao, Pranita Kaphle, Kathryn E Dickerson, Kirthi R Kumar, Mingyi Chen, Weina Chen, Eric Solary, Peter Ly, Jian Zhou, Jian Xu
RESUMEN

Structural variants (SVs) involving enhancer hijacking can rewire chromatin topologies to cause oncogene activation in human cancers, including hematologic malignancies; however, because of the lack of tools to assess their effects on gene regulation and chromatin organization, the molecular determinants for the functional output of enhancer hijacking remain poorly understood. Here, we developed a multimodal approach to integrate genome sequencing, chromosome conformation, chromatin state, and transcriptomic alteration for quantitative analysis of transcriptional effects and structural reorganization imposed by SVs in leukemic genomes. We identified known and new pathogenic SVs, including recurrent t(5;14) translocations that cause the hijacking of BCL11B enhancers for the allele-specific activation of TLX3 in a subtype of pediatric leukemia. Epigenetic perturbation of SV-hijacked BCL11B enhancers impairs TLX3 transcription, which are required for the growth of t(5;14) leukemia cells. By CRISPR engineering of patient-derived t(5;14) in isogenic leukemia cells, we uncovered a new mechanism whereby the transcriptional output of SV-induced BCL11B enhancer hijacking is dependent on the loss of DNA hypermethylation at the TLX3 promoter. Our results highlight the importance of the cooperation between genetic alteration and permissive chromatin as a critical determinant of SV-mediated oncogene activation, with implications for understanding aberrant gene transcription after epigenetic therapies in patients with leukemia. Hence, leveraging the interdependency of genetic alteration on chromatin variation may provide new opportunities to reprogram gene regulation as targeted interventions in human disease.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-TLX3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody